Credo’s FY27 Growth Narrative Faces a 80%+ Revenue Hurdle Amid Margin and Concentration Risks

What happened

A new Zacks article highlights Credo’s fiscal 2027 outlook for 80%+ revenue growth, strong margins, and rising R&D investment, led by its optical and copper portfolios. This growth projection far exceeds the base-case scenario in our prior deep-value analysis, which modeled 20-30% revenue growth and emphasized the need for auditable optical revenue evidence. The company’s own recent filings show only $31.9M in remaining performance obligations and 81% revenue concentration from two customers, making such a steep growth target highly dependent on a few large hyperscaler orders. Rising R&D spending—up 90% year-over-year to $279.4M in fiscal 2026—is a necessary investment for the optical and silicon photonics roadmap, but it pressures near-term profitability if revenue growth disappoints. The stock already trades at 105x earnings and 96x EV/EBITDA, so the market appears to be pricing in a successful optical ramp despite a lack of hard evidence to date.

Implication

If management has indeed guided to 80%+ revenue growth for fiscal 2027, that would imply roughly $2.4B in revenue, far above the $500M optical target and requiring an extraordinary acceleration in AEC shipments or a new hyperscaler win. Given that remaining performance obligations are only ~$32M and customers can cancel or change orders on short notice, such a projection likely relies on unbooked demand and carries significant execution risk. The margin outlook remains uncertain because rising R&D and DustPhotonics integration costs could compress gross margin below the guided 67-69% range, especially if optical products ramp with lower initial profitability. We would need to see at least two quarters of near-80% growth, stable gross margins, and customer concentration falling below 70% combined before considering the stock undervalued at current levels. Until then, the risk-reward remains unattractive; we maintain a WAIT stance and prefer an entry near $220, with a re-assessment if the company provides concrete optical revenue disclosures or lowers its growth expectations.

Thesis delta

The new article does not change our fundamental thesis but introduces a more aggressive growth target that we have not independently verified. If credible, it would shift our base case upward; however, without official confirmation or evidence of optical scale, the key risks—customer concentration, low visibility, and integration costs—remain unchanged. We therefore maintain a WAIT and require hard data to justify paying a premium valuation.